Cancer Research

Addition to COSMIC database collates drugs for target cancer mutations

25 March 2021

The Catalogue of Somatic Mutations in Cancer (COSMIC), based at the Wellcome Sanger Institute, has launched a new feature that will allow users to see which drugs are available to target specific cancer mutations. This new resource is a positive step towards making precision oncology possible for all cancer patients. The COSMIC Mutation Actionability in […]

Cancer immunotherapy may also treat autoimmune diseases

25 March 2021

A team of researchers has found disrupting the interaction between cancer cells and certain immune cells is more effective at killing cancer cells than current immunotherapy treatments. The findings, which include studies in cell lines and animal models, appeared in JCI Insight and focus on a protein called CD6 as a target for a new […]

CRISPR study identifies gene involved in metastasis of cancers to the lungs

23 March 2021

New research from scientists at the Wellcome Sanger Institute has shown a gene not previously linked to cancer plays a key role in the spread of certain cancers to the lungs. The team found that when the gene LRRN4CL was over-expressed in mice, the skin cancer melanoma was more likely to metastasise to the lungs. The study, […]

Consortium awarded EU Commission TIGER Grant of €6.9 million

22 March 2021

eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases, has announced the award of a TIGER grant of €6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer […]

Resistance-busting ICR drug enters clinical trial

19 March 2021

The Institute of Cancer Research (ICR), London, has discovered a drug that could counteract drug resistance in patients with cancers including acute myeloid leukaemia. It has entered a Phase I clinical trial at The Royal Marsden NHS Foundation Trust. The drug, now called EP0042, is a dual inhibitor of cancer-driving proteins from the Aurora and […]

Delaying second Pfizer-BioNTech dose could reduce cancer patients’ immunity

17 March 2021

More than half of cancer patients receiving a single dose of the Pfizer COVID-19 vaccine may be left with little protection against the virus, according to a new preprint from researchers at the Francis Crick Institute and King’s College London. Data from the world’s first reported trial to examine the level of immune protection after […]

Bicara Therapeutics launches biologics for cancer immunotherapy

16 March 2021

Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics designed to spur a potent and durable immune response in the tumour microenvironment, launched with a US$40 million investment from Biocon. The financing will be used to advance a pipeline of first-in-class bifunctional antibodies developed by a global team, including a biologics engineering team in Bangalore, […]

Immodulon presents on clinical biomarker strategies

15 March 2021

Immodulon, the immuno-oncology company, will present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event taking place virtually 24-25 March 2021. The presentation, titled ‘Clinical Biomarker Strategy with a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget’, will be presented at 12:45 CET, March 25, 2021, by its Chief Scientific Officer, […]

Avacta enters diagnostic licensing deal with Biokit

10 March 2021

Avacta, developer of cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms, has announced a licensing agreement with Biokit, to incorporate Affimer reagents into a Biokit in-vitro diagnostic (IVD) product. Biokit has experience in research, development and manufacturing of assays and biomaterial solutions for IVD use. Under the terms of the agreement […]

New study able to detect BRCA1 breast cells before they turn cancerous

10 March 2021

The earliest changes that occur in seemingly healthy breast tissue before tumours appear may have been found by researchers, suggests a new study published in Nature Communications. The study in mice, funded by Cancer Research UK, showed that before becoming cancerous, breast cells with the BRCA1 gene mutation undergo changes similar to those normally seen in […]

« Previous
Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free